{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-020635","form_type":"8-K","ticker":"OSUR","cik":"0001116463","company_name":"ORASURE TECHNOLOGIES INC","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.984386+00:00","generated_at":"2026-06-15T05:49:48.219961+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"OraSure Q1 record revenue $155M, GAAP EPS $0.37; guides Q2 rev $62-67M","bullets":["Total net revenue $155.0M (+129% YoY); InteliSwab revenue $118.3M (+33% sequential).","GAAP EPS $0.37, non-GAAP EPS $0.47; cash and short-term investments $112.4M.","Core business (ex-COVID) revenue $36.6M flat YoY; signed three new molecular partnerships.","2Q23 guidance: total revenue $62-67M, InteliSwab $25-30M; cost savings beyond $15M targeted.","Gross margin 42.5% GAAP, up 200bps sequential; packaging changes expected to save ~$0.50/test."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-020635","json":"https://secwatch.observer/filing/0000950170-23-020635.json","markdown":"https://secwatch.observer/filing/0000950170-23-020635.md","text":"https://secwatch.observer/filing/0000950170-23-020635.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1116463/000095017023020635/0000950170-23-020635-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1116463/000095017023020635/osur-20230510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T05:49:48.219961+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e4aa834ee4de1597b2f86b14b43db4494412086a","claim":"ORASURE TECHNOLOGIES INC reported three months ended March 31, 2023 results: revenue $ 154,963, net income 27,219, EPS $ 0.37.","evidence_excerpt":"Three Months Ended March 31, 2023 2022 % Change Core Business $ 36,554 $ 36,675 0 % COVID-19 118,409 31,032 282 Total Net Revenue $ 154,963 $ 67,707 129 % Three Months Ended March 31, 2023 2022 % Change Net revenues $ 154,963 $ 67,707 129 % Gross profit 65,815 24,299 171 Gross margin 42.5 % 35.9 % Non-GAAP gross profit 66,277 25,527 160 Non-GAAP gross margin 42.8 % 37.7 % Operating income (loss) 24,321 (16,172 ) NM Operating margin 15.7 % -23.9 % Non-GAAP operating income (loss) 32,658 (6,584 ) NM Non-GAAP operating income (loss) 21.1 % -9.7 % Net income (loss) 27,219 (19,940 ) NM Non-GAAP net income (loss) 34,454 (10,662 ) NM GAAP EPS $ 0.37 $ (0.28 ) NM Non-GAAP EPS $ 0.47 $ (0.15 ) NM","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1116463/000095017023020635/0000950170-23-020635-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2023"},{"label":"Revenue","value":"$ 154,963"},{"label":"Net income","value":"27,219"},{"label":"EPS","value":"$ 0.37"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}